Get the Stockscreener App
1.54
2.67%
0.04
After Hours:
1.52
-0.02
-1.30%
Prokidney Corp stock is traded at $1.54, with a volume of 1.24M.
It is up +2.67% in the last 24 hours and down -15.85% over the past month.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$1.50
Open:
$1.53
24h Volume:
1.24M
Relative Volume:
1.12
Market Cap:
$316.01M
Revenue:
$889.00K
Net Income/Loss:
$-156.28M
P/E Ratio:
-2.9239
EPS:
-0.5267
Net Cash Flow:
$-150.06M
1W Performance:
-1.28%
1M Performance:
-15.85%
6M Performance:
-30.32%
1Y Performance:
-53.19%
1-Day Range:
$1.52
$1.61
1-Week Range:
$1.45
$1.61
52-Week Range:
$1.45
$3.55
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.54 | 307.80M | 889.00K | -156.28M | -150.06M | -0.5267 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | H.C. Wainwright | Buy |
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
ProKidney Corp (PROK) Income Statement - TradingKey
ProKidney Corp (PROK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PROK|ProKidney Corp|Price:1.500|Chg%:-0.020 - TradingKey
ProKidney Corp (PROK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProKidney Corp (PROK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ProKidney Corp (PROK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
ProKidney Corp (PROK) Cash Flow - TradingKey
PROK|ProKidney Corp|Price:1.504|Chg%:+0.004 - TradingKey
ProKidney Corp (PROK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProKidney (NASDAQ:PROK) Trading Down 0.7%Time to Sell? - MarketBeat
ProKidney Corp. (PROK) Q1 2026 Earnings: In-Line EPS, Pre-Revenue Progress Drives Modest Stock GainROA Comparison - dars.gov.et
Meet the Biotech Stock That Rocketed 775% Higher - MSN
ProKidney Corp (PROK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProKidney Corp. Q1 2026 Earnings: Clinical-Stage Biotech Posts Narrower-Than-Expected Loss, Shares RallyEPS Revision Trend - dars.gov.et
ProKidney Corp. (PROK) Declines Sharply: Key Support Level Under ScrutinyMFI Overbought - dars.gov.et
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrowed Loss Slightly Beats Estimates Amid Pipeline Focus - dars.gov.et
ProKidney (NASDAQ:PROK): Can This Penny Stock Rebound? - Kalkine Media
What Makes ProKidney Corp (NASDAQ:PROK) Stand Out on Nasdaq Composite? - Kalkine Media
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEstimate Uncertainty - dars.gov.et
ProKidney (PROK) 43rd Annual J.P. Morgan Healthcare Conference 2025 Summary - Quartr
ProKidney (NASDAQ: PROK) CTO awarded 750,000 stock options at $1.89 strike - Stock Titan
July 2026 Penny Stocks With Promising Potential - simplywall.st
PROK Q1 2026 Earnings: EPS Slightly Exceeds Estimates as Clinical Progress ContinuesRevenue Guidance Range - dars.gov.et
PROKProKidney Corp Short Interest - Finviz
Is ProKidney (NASDAQ:PROK) In A Good Position To Invest In Growth? - 富途牛牛
ProKidney Corp. (PROK) Rallies 7.4%: Biotech Stock Approaches Key Resistance LevelFactor Crowding - dars.gov.et
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrower Loss, No Revenue, Shares Gain Post-ReportEarnings Call Highlights - dars.gov.et
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Value Benchmark Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Value Benchmark - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Growth Benchmark Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Growth Benchmark - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell 3000E Growth Benchmark - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2500 Value Benchmark - marketscreener.com
Price to earnings forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Price to earnings forward of ProKidney Corp. Class A – BMV:PROK - TradingView
Price to sales forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Enterprise value to revenue forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Enterprise value to EBIT forward of ProKidney Corp. Class A – BMV:PROK - TradingView
Enterprise value to EBITDA forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Price to sales forward of ProKidney Corp. Class A – BMV:PROK - TradingView
ProKidney Corp (PROK) Valuation: PE, PB & Fair Value Analysis - TradingKey
ProKidney Corp. Class A Actuals & Estimates (NASDAQ:PROK) - TradingView
ProKidney Corp. (PROK) Faces Selling Pressure Near Resistance – Key Levels in FocusDouble EMA - dars.gov.et
PROK Forecast — Price Target — Prediction for 2027 - TradingView
ProKidney (PROK) Study Update Summary - Quartr
ProKidney Corp (PROK) Institutional Confidence - TradingKey
ProKidney Corp. (PROK) Slips 1.67% as Stock Tests Key Support at $1.68Fast Moving Stocks - dars.gov.et
PROK Q1 2026 Earnings: Narrower Loss Than Expected Lifts SharesEPS Miss Report - dars.gov.et
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):